On Our Radar: August Clinical Trials | Fight CRC
First paragraph of text goes here until the bar below is green.| Fight CRC
Zemcelpro, a cord blood-sourced cell therapy developed by startup ExCellThera, received conditional marketing authorization in Europe as a treatment for blood cancer patients who can’t find a matched donor. It’s the first cell therapy approved in Europe for this group of patients. The post European Commission Approval Gives Blood Cancer Patients a New Cell Therapy Option appeared first on MedCity News.| MedCity News
Cemdisiran, a small interfering RNA drug that Regeneron Pharmaceuticals licensed from Alnylam Pharmaceuticals, met the goals of its pivotal test in generalized myasthenia gravis. The rare neuromuscular disease has several new therapies, but analysts see cemdisiran as having advantages over one particular class of drugs. The post Regeneron’s RNA Med for Muscle Disease Meets Trial Goals; FDA Filing Planned for Next Year appeared first on MedCity News.| MedCity News
First paragraph of text goes here until the bar below is green.| Fight CRC
Peter Barton Hutt, former Chief Counsel at the FDA and pioneer of medical device regulatory policy, joins as Plan A™ concludes successful U.S. clinical trials. Los Angeles, CA – August 27, 2025 – NEXT Life Sciences, the modern reproductive healthcare company pioneering Plan A™, a first-of-its-kind, long-lasting, and on-demand-reversible male contraceptive, announced today the addition […]| TechBullion
LB Pharmaceuticals’ planned IPO will fund late-stage clinical development of LB-102, a once-daily pill designed to improve on the old Sanofi schizophrenia drug Solian. The IPO filing follow a corporate restructuring in May that cut the jobs of LB’s chief financial and scientific officers to streamline operations and extend its cash runway. The post With a New Take on an Old Schizophrenia Drug, LB Pharma Prepares IPO to Fund Phase 3 Test appeared first on MedCity News.| MedCity News
Novartis' therapy candidate ianalumab safely and effectively eased disease activity for adults with active Sjögren's in two clinical trials.| Sjogren's Disease News
In this episode of Still Here: Betsy Ladyzhets and Miles Griffis recap the Keystone Symposia. Plus, a recap of a new NIH RECOVER preprint about reinfections. The post Still Here, August 22: Links and transcript first appeared on The Sick Times.| The Sick Times
Last week, leading Long COVID and infection-association chronic condition (IACC) researchers met in Santa Fe, New Mexico, for the field’s second Keystone Symposia meeting. They were joined by advocates, clinicians, and representatives from pharmaceutical companies for a three-day conference focused on sharing new research and building consensus. The post “The field is coming of age”: Long COVID researchers gather in Santa Fe to foster collaboration first appeared on The Sick Times.| The Sick Times
A new preprint from the National Institutes of Health (NIH) RECOVER study found that COVID reinfections may increase the risk of Long COVID by about 35%. The post Research updates, August 19 first appeared on The Sick Times.| The Sick Times
In this episode of Still Here: A two-way between Miles Griffis and Betsy Ladyzhets comparing and contrasting Long COVID and ME clinical trial designs for drugs targeting immune dysregulation and viral persistence. The post Still Here, August 19: Links and transcript first appeared on The Sick Times.| The Sick Times
While three early clinical trials of these drugs did not find they led to health improvements for participants, further trials are getting more intentional in targeting viral persistence. The post No “easy home runs”: Early Long COVID trials of Paxlovid and monoclonal antibodies failed, but the treatments still have potential first appeared on The Sick Times.| The Sick Times
People with myalgic encephalomyelitis (ME) have significant genetic differences in their DNA, according to a preprint shared this week from the DecodeME study. The post Research updates, August 12 first appeared on The Sick Times.| The Sick Times
The Ministry of Health will begin using real-world evidence like treatment outcomes from hospitals to inform drug listings in the MOH formulary, moving away from relying on clinical trial data alone in a shift towards value-based care and patient outcomes. The post MOH To Use Real-World Evidence In Blue Book Drug Listing appeared first on CodeBlue.| CodeBlue
The U.S. FDA has granted orphan drug designation to CS1, Cereno Scientific’s lead therapy candidate for treating pulmonary arterial hypertension (PAH).| Pulmonary Hypertension News
While diagnostic pathologists can review scanned slides remotely with AI assistance and instant global collaboration, much of the clinical trial pathology world still ships physical glass slides between labs, dealing with FedEx delays and proprietary file formats. “For exploratory assays, yes, it’s exploding. Everyone’s enjoying artificial intelligence and machine learning for various aspects, but there’s… The post Digital ready, regulatory waiting: The clinical trial pathology para...| Drug Discovery and Development
Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s room for many MASH drugs with the treatment landscape expected to shape up to include combinations of therapies bringing different approaches to this fatty liver disease.| MedCity News
Investigators receive $5 million research grant to explore ways to use artificial intelligence to accelerate and improve screening and treatment for cardiovascular disease. The post American Heart Association funds Kaiser Permanente to study AI in cardiovascular care appeared first on Kaiser Permanente Division of Research.| Kaiser Permanente Division of Research
Ongoing clinical research study in US children documents the rebound of endemic respiratory viruses, builds foundation for expediting future vaccines and treatments. Continue reading| Newsroom
One global clinical trial testing astegolimab for moderate to severe COPD hit its main goal, but another did not, Genentech reports.| COPD News Today
The Phase 1 clinical trial is expected to enroll up to 18 children between 4 and 18 years old with pediatric high-grade gliomas.| Cancer Center » UF Health Cancer Center » University of Florida
“At the time of the episode,” Dr. Levin said at the conference, “Subject C didn’t recall it was her birthday. When prompted, she said, ‘I feel like an invalid.’” It was, he noted, a revealing momen…| The Skeptic's Kaddish 🇮🇱
A study from the Barcelona Institute for Global Health revealed that ivermectin, usually used to treat river blindness and scabies, can reduce malaria transmission. The BOHEMIA trial is the largest study on ivermectin for malaria, and results revealed that the pill reduced malaria by 26%. As mosquitoes become more resistant to insect repellent and other… The post This pill makes blood deadly to mosquitoes and reduced malaria by 26% appeared first on Drug Discovery and Development.| Drug Discovery and Development
Diverse clinical trials lead to better, safer treatments that reflect the real-world needs of all lupus patients. Here’s why – and how you can help make a difference. The post Why Diversity in Clinical Trials Matters for Lupus Patients Like You appeared first on CreakyJoints.| CreakyJoints
Eligibility, principal investigator, placebos, and informed consent — learning these key terms and more may help you understand and feel more confident about clinical trials. The post The Language of Clinical Trials appeared first on CreakyJoints.| CreakyJoints
On February 26, 2016, the first version of an article titled “How blockchain-timestamped protocols could improve the trustworthiness of medical science” was posted to F1000Research. The paper had two authors: Greg Irving of the University of Cambridge and John Holden of Garswood Surgery. The article describes a method for timestamping clinical trials, so the retrospective existence of a trial can be verified at a later date. The technique uses the Bitcoin blockchain as an immutable …| Satoshi Village
Research Science Liaisons – We’re like MSLs, Only the Opposite When we first meet with Medical Science Liaisons (MSLs), they are often confused about our role. We can’t blame them – our position is unique and very few cancer centers have a role like ours. Our 30-second “pitch” to MSLs is always “We are like […]| THE MSL
Immunotherapy is becoming a more prominent option for people with breast cancer, especially those with certain subtypes of breast cancer.| Susan G. Komen®
Top-line results are expected later this month.| Sleep Review
Alkermes’ alixorexton met primary and key secondary endpoints in a phase 2 trial for narcolepsy type 1, showing dose-dependent improvements.| Sleep Review
Demand for next-generation GLP-1 drugs is fueling a boom in peptide research, prompting companies like Sai Life Sciences to expand capabilities amid a hot market for obesity and diabetes treatments. “The GLP-1 agonists have exploded the peptide field,” said Maneesh Pingle, Ph.D., executive vice president and head of discovery services at Sai Life Sciences, in… The post Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center appeared first on Drug...| Drug Discovery and Development
Swissmedic has approved Novartis’ Coartem Baby as the first malaria medicine for newborns and young infants, the company announced on Tuesday. The treatment was developed in collaboration with the Medicines for Malaria Venture (MMV). Novartis plans to distribute the treatment on a not-for-profit basis to areas where malaria is endemic. This includes the eight African… The post Swissmedic approves first malaria treatment for infants appeared first on Drug Discovery and Development.| Drug Discovery and Development
Every year, the UC Irvine Committee on Scholarly Honors and Awards selects the recipients of the Academic Senate Distinguished Faculty Awards. This year two UCI MIND faculty have been recognized: Distinguished Senior Faculty Award for Research Chancellor’s Professor Emeritus Leslie Thompson Department of Neurobiology and Behavior, Charlie Dunlop School of Biological Sciences Department of Psychiatry & Human Behavior, School of Medicine Distinguished Mid-Career Faculty Award for Resear...| UCI MIND
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.| Drug Discovery and Development
Unravel Biosciences' agreement with Quality Chemical Laboratories will work toward manufacturing materials for clinical trials of RVL001.| Rett Syndrome News
On Thursday, June 26th, 2025, UCI Chancellor Howard Gillman announced the appointment of Professor of Physical Medicine & Rehabilitation and UCI MIND faculty member, Aileen Anderson, PhD, as the vice chancellor for research. “Throughout her distinguished career, Professor Anderson has demonstrated a strong commitment to fostering a thriving, inclusive and interdisciplinary research environment. She has a proven track record in building research infrastructure, supporting faculty and train...| UCI MIND
Memory loss in dementia presents challenges but clinical trials are paving the way for new treatment options that slows cognitive decline.| Princeton Medical Institute
Tuo Lin, Ph.D., aims to strengthen his collaboration skills in designing early-phase and pragmatic oncology trials.| cancer.ufl.edu
Dupixent (dupilumab) has been approved by the FDA for the treatment of adult patients with bullous pemphigoid.| Drug Discovery and Development
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
The FDA has approved zoliflodacin for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older.| Drug Discovery and Development
The FDA has approved ENFLONSIA for the prevention of RSV lower respiratory tract disease in infants and newborns.| Drug Discovery and Development
This post is the latest in my series of “Wow! How? Health” stories, also shared on LinkedIn if you want to follow the conversation on that platform. When Michael Katz was diagnosed with multiple myeloma, he was fortunate to connect with someone who had recently completed treatment, the “just-in-time someone-like-me” that could guide him. He vowed to do the […]| Susannah Fox
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
Health agencies working under Robert F. Kennedy Jr. are making changes to the nation's decades-old system for approving and recommending vaccines.| AP News
Explore innovative osteosarcoma treatment options for dogs, highlighting histotripsy and the importance of community support.| IVC Journal
Labcorp rolls out new NGS panels, HRD testing, and a Leica-Proscia digital pathology platform to accelerate biomarker screening.| Drug Discovery and Development
Explore the differences between Risk-Based Monitoring (RBM) and 100% Source Data Verification (SDV) for clinical trials| dicentra
May 02, 2005 Original Source: https://www.democracynow.org/2005/5/2/hundreds_of_hiv_foster_children_in| Message to Germany | Alliance for Human Research Protection
This month we feature clinical trials for colorectal cancer patients with minimal residual disease (MRD) after curative-intent treatment. MRD| Fight CRC
A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy wanes from season to season. Despite this, just a single dose cut serious illness by nearly two thirds, and…| New Atlas
Learn what a Clinical Research Feasibility Assessment (CRFA) is and how it helps sponsors plan, evaluate, and de-risk clinical trials.| dicentra
The primary objective of ERASur is to answer this question – Do patients with limited metastatic colorectal cancer live longer if| Fight CRC
The trial will test a novel UF-developed mRNA lipid nanoparticle (RNA-LP) in two pediatric cancers.| cancer.ufl.edu
A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in people with a genetic predisposition to the devastating condition. Right now, symptoms are almost 100% likely to develop in patients between the ages of 30 and 65.| New Atlas
We learned much more about the role of circulating tumor DNA (ctDNA) tests in treating colorectal cancer at this meeting. I’m looking forward| Fight CRC
Advances in ADHD treatment are rapidly evolving, thanks to groundbreaking clinical trials that are uncovering more personalized and effective approaches. From innovative medications with fewer side effects to digital therapies and neurofeedback, these developments are opening up new possibilities for managing ADHD. Here’s how clinical trials are leading the way in shaping the future of … Current Advances in ADHD Treatment: How Clinical Trials Are Leading the Way Read More »| Princeton Medical Institute
Breast cancer treatment isn’t one-size-fits-all. Personalized care is tailored to you. Learn more about tailored plans and treatment.| Susan G. Komen®
Update 2025-02-07: This article is now available on OSF Preprints Update 2025-01-31: A French translation of this article is available here CORRELATION has published a new report entitled “Op…| CORRELATION
Alzheimer’s and dementia are complex, progressive conditions that impact millions of individuals and their families around the world. In the pursuit of effective treatments, clinical trials play an essential role, driving advancements in care, expanding treatment options, and offering hope to those affected. Through rigorous testing and research, clinical trials not only pave the way … The Role of Clinical Trials in Advancing Alzheimer’s and Dementia Care Read More »| Princeton Medical Institute
A six-month follow-up study of a Phase 2 clinical trial investigating psilocybin versus escitalopram for the treatment of major depressive disorder has shown positive results. The post Psilocybin versus escitalopram for depression shows positive results appeared first on Psychedelic Health.| Psychedelic Health
Where do energy transition and life-saving medicine meet? In Texas, of course.| InnovationMap
Cancer treatment in Houston just became even more promising — and forward-thinking.| InnovationMap
Dyne Therapeutics, Inc. has announced positive new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne who are amenable to exon 51 skipping. DYNE-251 is an exon skipping product...| Parent Project Muscular Dystrophy
Repare Therapeutics is cutting discovery and preclinical work to focus on its clinical-stage cancer drugs. The most advanced program is camonsertib, whose rights Repare recently regained from Roche after the pharma giant terminated an alliance started in 2022.| MedCity News
Two ALS centers launched an initiative to expand access to clinical trials and accelerate improvements in ALS research.| ALS News Today
Tetra Therapeutics has amended the protocols of two ongoing clinical trials testing zatolmilast to improve access for fragile X patients.| Fragile X News Today
Ever wondered how much you could earn by participating in a psychedelic clinical trial? Let's break down the potential earnings| HealingMaps
Kristy Phillips, founder and CEO of Clean Habits, is bringing a natural cleaning solution to United States homes and farms.| InnovationMap
Message from the Director Dear Friends of UCI MIND, Please enjoy the latest issue of MIND Matters from UCI MIND. In this Spring issue, we highlight a number of exciting updates about the impact UCI MIND investigators are having in the field. On the cover, post-doctoral fellow Dr. Claire Butler highlights progress made by the collaborative MODEL-AD group, including a publication she led. Another post-doctoral fellow, Dr. Jessica Noche, highlights an exciting collaboration in which UCI MIND ...| UCI MIND
Clinical trial results have a greater impact when participants reflect the diversity of those who could potentially benefit from the treatments being evaluated. Community-based trials can help achieve that.| STAT
An influential study from Argentina has been used to argue that ivermectin prevents COVID 100% of the time — but its inconsistencies have led experts to question if it could have actually happened as advertised.| BuzzFeed News
As result of a commentary we wrote, Jama Psychiatry recently published a correction of a serious error in a 2023 paper on treating bipolar depression with psilocybin (together with Ioana Cristea and Florian Naudet). This correction included correcting the title of the paper itself. In this blog, I’ll very briefly discuss the core issue in... Read more »| Eiko Fried
A 2022 study on psilocybin has received a lot of criticism by the scientific community, but authors or journal have not corrected the record.| Eiko Fried
In a new systematic review, we compare 388 depression outcomes from 450 clinical trials to see which perform best.| Eiko Fried
I recently noticed that the Pfizer immunobridging trials, presumably set up to demonstrate that their COVID-19 vaccines elicit the same antibody response in children as was seen in 16-25 year olds, for whom efficacy has previously been demonstrated, have a strange criteria for “success”. GMT: geometric mean titer. This is a measure of the antibody titers. We use the geometric mean because this data is quite skewed (it is also why you typically see it plotted on the log scale). For those o...|
Message from the Director Dear Friends of UCI MIND, Happy New Year! We hope that 2024 is off to a positive start for you. As we embark upon a new year, UCI MIND and the field of Alzheimer’s disease and related dementias (ADRD) research are abuzz with excitement about progress made and opportunities to further advance our field. At the end of 2023, we held our annual signature fundraising event, the December to Remember Gala. We honored Lauren Miller Rogen and Seth Rogen, the founders of H...| UCI MIND
Studies claim psychedelics provide effective treatments against depression. Here I show you why this is not the case.| Eiko Fried
